Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
BackgroundHigh-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. In this work, we developed noninvasive imagingbased measurements of spatia...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1546324/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132976627613696 |
|---|---|
| author | Maria Delgado-Ortet Maria Delgado-Ortet Vlad Bura Vlad Bura Vlad Bura Vlad Bura Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana David Hulse David Hulse David Hulse Leonardo Rundo Leonardo Rundo Leonardo Rundo James D. Brenton James D. Brenton James D. Brenton James D. Brenton Evis Sala Evis Sala Evis Sala Evis Sala Evis Sala Lorena Escudero Sanchez Lorena Escudero Sanchez |
| author_facet | Maria Delgado-Ortet Maria Delgado-Ortet Vlad Bura Vlad Bura Vlad Bura Vlad Bura Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana David Hulse David Hulse David Hulse Leonardo Rundo Leonardo Rundo Leonardo Rundo James D. Brenton James D. Brenton James D. Brenton James D. Brenton Evis Sala Evis Sala Evis Sala Evis Sala Evis Sala Lorena Escudero Sanchez Lorena Escudero Sanchez |
| author_sort | Maria Delgado-Ortet |
| collection | DOAJ |
| description | BackgroundHigh-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).MethodsLesions identified in CT images at baseline, week 4 (after PARPi only) and week 12 (after 8 weeks of PARPi + ICIs) were manually segmented. Anatomical networks of the metastatic sites were constructed to represent patterns of disease distribution. Volume and first-order radiomic features were computed and compared to different assessments of treatment response.ResultsThe average number of edges per patient in the anatomical networks and total volumetric burden decreased with treatment were measured, differentiating between responders and nonresponders. Changes in volume at week 4 provided better indication of long-term response than the default RECIST assessment at the same time-point. Significant differences were also found between responders and non-responders in the first-order radiomic feature Energy.ConclusionsIn this feasibility study, we have demonstrated that noninvasive image-based analysis can identify quantitative imaging features associated with the response to the combination of PARPi and ICIs. These can be used to identify markers of response to ICIs from negative trials of a disease with limited response to ICIs. |
| format | Article |
| id | doaj-art-222e45f6bc2a4fb894d719234ff679e5 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-222e45f6bc2a4fb894d719234ff679e52025-08-20T02:32:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15463241546324Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patientsMaria Delgado-Ortet0Maria Delgado-Ortet1Vlad Bura2Vlad Bura3Vlad Bura4Vlad Bura5Ionut-Gabriel Funingana6Ionut-Gabriel Funingana7Ionut-Gabriel Funingana8Ionut-Gabriel Funingana9David Hulse10David Hulse11David Hulse12Leonardo Rundo13Leonardo Rundo14Leonardo Rundo15James D. Brenton16James D. Brenton17James D. Brenton18James D. Brenton19Evis Sala20Evis Sala21Evis Sala22Evis Sala23Evis Sala24Lorena Escudero Sanchez25Lorena Escudero Sanchez26Department of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomDepartment of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomCambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United KingdomDepartment of Radiology, Clinical Emergency Hospital for Children, Cluj-Napoca, RomaniaCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomCambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United KingdomDepartment of Oncology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Institute, CRUK and University of Cambridge, Cambridge, United KingdomDepartment of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomCambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United KingdomDepartment of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomDepartment of Information and Electrical Engineering and Applied Mathematics, University of Salerno, Fisciano, ItalyCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomCambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United KingdomDepartment of Oncology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Institute, CRUK and University of Cambridge, Cambridge, United KingdomDepartment of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomCambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United KingdomDipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyDipartimento di Scienze Radiologiche ed Ematologiche, Universita Cattolica del Sacro Cuore, Rome, ItalyDepartment of Radiology, University of Cambridge, Cambridge, United KingdomCancer Research UK Cambridge Centre, CRUK and University of Cambridge, Cambridge, United KingdomBackgroundHigh-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).MethodsLesions identified in CT images at baseline, week 4 (after PARPi only) and week 12 (after 8 weeks of PARPi + ICIs) were manually segmented. Anatomical networks of the metastatic sites were constructed to represent patterns of disease distribution. Volume and first-order radiomic features were computed and compared to different assessments of treatment response.ResultsThe average number of edges per patient in the anatomical networks and total volumetric burden decreased with treatment were measured, differentiating between responders and nonresponders. Changes in volume at week 4 provided better indication of long-term response than the default RECIST assessment at the same time-point. Significant differences were also found between responders and non-responders in the first-order radiomic feature Energy.ConclusionsIn this feasibility study, we have demonstrated that noninvasive image-based analysis can identify quantitative imaging features associated with the response to the combination of PARPi and ICIs. These can be used to identify markers of response to ICIs from negative trials of a disease with limited response to ICIs.https://www.frontiersin.org/articles/10.3389/fonc.2025.1546324/fullovarian cancerPARP inhibitorsimmunotherapyradiomicscomputed tomography |
| spellingShingle | Maria Delgado-Ortet Maria Delgado-Ortet Vlad Bura Vlad Bura Vlad Bura Vlad Bura Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana Ionut-Gabriel Funingana David Hulse David Hulse David Hulse Leonardo Rundo Leonardo Rundo Leonardo Rundo James D. Brenton James D. Brenton James D. Brenton James D. Brenton Evis Sala Evis Sala Evis Sala Evis Sala Evis Sala Lorena Escudero Sanchez Lorena Escudero Sanchez Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients Frontiers in Oncology ovarian cancer PARP inhibitors immunotherapy radiomics computed tomography |
| title | Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients |
| title_full | Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients |
| title_fullStr | Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients |
| title_full_unstemmed | Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients |
| title_short | Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients |
| title_sort | imaging based assessment of response to olaparib in platinum sensitive relapsed ovarian cancer patients |
| topic | ovarian cancer PARP inhibitors immunotherapy radiomics computed tomography |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1546324/full |
| work_keys_str_mv | AT mariadelgadoortet imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT mariadelgadoortet imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT vladbura imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT vladbura imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT vladbura imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT vladbura imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT ionutgabrielfuningana imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT ionutgabrielfuningana imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT ionutgabrielfuningana imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT ionutgabrielfuningana imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT davidhulse imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT davidhulse imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT davidhulse imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT leonardorundo imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT leonardorundo imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT leonardorundo imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT jamesdbrenton imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT jamesdbrenton imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT jamesdbrenton imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT jamesdbrenton imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT evissala imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT evissala imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT evissala imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT evissala imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT evissala imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT lorenaescuderosanchez imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients AT lorenaescuderosanchez imagingbasedassessmentofresponsetoolaparibinplatinumsensitiverelapsedovariancancerpatients |